Agiolax mite (ohne Senna)

Hauptinformation

  • Handelsname:
  • Agiolax mite (ohne Senna) Granulat
  • Darreichungsform:
  • Granulat
  • Zusammensetzung:
  • Wegerich ovatae semen 3.25 g, Wegerich ovatae semen tester 110 mg, synthetischen 855 mg, excipiens ad granulatum für 5 g.
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • Pflanzliches für Menschengebrauch

Dokumenten

Lokalisierung

  • Erhältlich in:
  • Agiolax mite (ohne Senna) Granulat
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Phytoarzneimittel
  • Therapiebereich:
  • Zur Stuhlregulierung, bei Verstopfung

Weitere Informationen

Status

  • Quelle:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Zulassungsnummer:
  • 42933
  • Berechtigungsdatum:
  • 21-03-1980
  • Letzte Änderung:
  • 24-10-2018

Packungsbeilage

Patienteninformation

Agiolax® mite ohne Senna Granulat

MEDA Pharma GmbH

Pflanzliches Arzneimittel

Was ist Agiolax mite und wann wird es angewendet?

Agiolax mite ist ein pflanzliches Quell- und Gleitmittel aus Flohsamen und Flohsamenschalen

(Plantago ovata Samen und Samenschalen).

Agiolax mite wird angewendet zur sanften Anregung der Darmtätigkeit bei Reizkolon,

Divertikulose; Verstopfung bei Schwangerschaft und Wochenbett; Diät, Fastenkuren, Bettlägerigkeit

und Rekonvaleszenz; zur schonenden Darmentleerung bei Hämorrhoiden, Analfissuren; chronischer

Verstopfung. Agiolax mite bewirkt eine Stuhlvolumenvergrösserung im Darm. Die Inhaltsstoffe der

Granulatkörnchen quellen bei Wasseraufnahme um ein Vielfaches ihres Volumens auf. Dadurch

wird die Darmtätigkeit angeregt und ein geschmeidiger, weicher Darminhalt erzeugt.

Was sollte dazu beachtet werden?

Achten Sie auf genügend Flüssigkeitsaufnahme!

Bei gleichzeitiger Verabreichung von anderen Arzneimitteln kann eine verzögerte Aufnahme

stattfinden. Deshalb sollte vor der Anwendung von Agiolax mite ein Abstand von einer halben bis

einer Stunde nach der Einnahme von anderen Arzneimitteln eingehalten werden.

Dieses Arzneimittel enthält 0.9 g verwertbare Kohlenhydrate pro 5 g Granulat (ca. 1 Teelöffel).

Wenn Sie an Verstopfung leiden, sollten Sie

·ballaststoffreiche Nahrung (Gemüse, Früchte, Vollkornbrot) zu sich nehmen,

·viel und regelmässig Flüssigkeit einnehmen und

·auf körperliche Betätigung (Sport) achten!

Wann darf Agiolax mite nicht oder nur mit Vorsicht eingenommen werden?

Agiolax mite darf nicht eingenommen werden bei Darmverschluss (Ileus), krankhaften Verengungen

im Magen-Darm-Trakt, Zwerchfellbruch (Hiatushernie), bei Bauchschmerzen unbekannter Ursache,

schwer einstellbarer Zuckerkrankheit (Diabetes mellitus).

Kinder unter 6 Jahren dürfen Agiolax mite nicht einnehmen.

Quellmittel und darmbewegungshemmende Mittel gegen Durchfall, z.B. Diphenoxylat, Diphenoxin,

Loperamidhydrochlorid und Opiate dürfen nicht gleichzeitig verabreicht werden (Gefahr des

Darmverschlusses).

Wenn Sie unter chronischer Verstopfung leiden, empfiehlt es sich, den Arzt oder die Ärztin

aufzusuchen.

Informieren Sie Ihren Arzt, Apotheker oder Drogisten bzw. Ihre Ärztin, Apothekerin oder Drogistin,

wenn Sie

·an andern Krankheiten leiden,

·Allergien haben oder

·andere Arzneimittel (auch selbstgekaufte!) einnehmen.

Darf Agiolax mite während einer Schwangerschaft oder in der Stillzeit eingenommen werden?

Agiolax mite darf während der Schwangerschaft und in der Stillzeit eingenommen werden.

Wie verwenden Sie Agiolax mite?

Erwachsene: Abends nach dem Essen (spätestens 1 Std. vor dem Zubettgehen) 2 Teelöffel und bei

Bedarf zusätzlich 1 bis 2 Teelöffel vor dem oder zum Frühstück.

Kinder: ab 6 Jahren die halbe Dosis.

Granulat unzerkaut mit reichlich Flüssigkeit (mind. 150 ml, d.h. ein grosses Glas) einnehmen

(Wasser, Tee, Kaffee, Milch, Fruchtsaft). Das Granulat kann auch mit Joghurt vermischt

eingenommen werden. Zusätzlich sollte reichlich Flüssigkeit getrunken werden.

Halten Sie sich an die in der Packungsbeilage angegebene oder vom Arzt bzw. von der Ärztin

verschriebene Dosierung. Wenn Sie glauben, das Arzneimittel wirke zu schwach oder zu stark, so

sprechen Sie mit Ihrem Arzt, Apotheker oder Drogisten bzw. mit Ihrer Ärztin, Apothekerin oder

Drogistin.

Welche Nebenwirkungen kann Agiolax mite haben?

Folgende Nebenwirkungen können bei der Einnahme von Agiolax mite auftreten:

Gelegentlich können während der ersten Behandlungstage Blähungen und Völlegefühl auftreten.

Diese Beschwerden klingen aber im Verlauf der weiteren Anwendung ab. In seltenen Fällen können

Überempfindlichkeitsreaktionen (Hautrötung, Jucken, Ekzem) auftreten. In diesem Falle ist sofort

ein Arzt bzw. eine Ärztin zu informieren.

Wenn Sie Nebenwirkungen bemerken, die hier nicht beschrieben sind, sollten Sie Ihren Arzt,

Apotheker oder Drogisten bzw. Ihre Ärztin, Apothekerin oder Drogistin informieren.

Was ist ferner zu beachten?

Arzneimittel für Kinder unzugänglich aufbewahren.

Bei Raumtemperatur (15-25 °C) lagern. Den Behälter fest verschlossen halten.

Das Arzneimittel darf nur bis zu dem auf dem Behälter mit «EXP» bezeichneten Datum verwendet

werden.

Weitere Auskünfte erteilt Ihnen Ihr Arzt, Apotheker oder Drogist bzw. Ihre Ärztin, Apothekerin oder

Drogistin. Diese Personen verfügen über die ausführliche Fachinformation.

Bei chronischer Verstopfung empfiehlt es sich einen Arzt bzw. eine Ärztin aufzusuchen, der/die

möglicherweise eine ursächliche Behandlung durchführen kann.

Was ist in Agiolax mite enthalten?

5 g Granulat (ca. 1 Teelöffel) enthalten:

Indische Flohsamen (Plantaginis ovatae semen) 3,25 g,

Indische Flohsamenschalen (Plantaginis ovatae semenis tegumentum) 0,11 g.

Dieses Präparat enthält zusätzlich Hilfsstoffe und Aromen (Kümmel-, Salbei, Pfefferminzöl).

5 g Granulat (ca. 1 Teelöffel) enthalten 0,9 g Saccharose.

Zulassungsnummer

42933 (Swissmedic).

Wo erhalten Sie Agiolax mite? Welche Packungen sind erhältlich?

In Apotheken und Drogerien, ohne ärztliche Verschreibung.

In Packungen zu 250 g, 400 g und 1000 g Granulat.

Zulassungsinhaberin

MEDA Pharma GmbH, 8021 Wangen-Brüttisellen.

Herstellerin

MADAUS GmbH, D-51101 Köln.

Diese Packungsbeilage wurde im Mai 2006 letztmals durch die Arzneimittelbehörde (Swissmedic)

geprüft.

3-4-2018

Three new reimbursement guidelines

Three new reimbursement guidelines

The Danish Medicines Agency has issued three new guidelines on reimbursement (in Danish only). This regards Guideline on application for general reimbursement and general conditional reimbursement, Guideline on periodic reassessment of the reimbursement status of medicines and Guideline on the making of health economic analyses of medicines.

Danish Medicines Agency

22-2-2012

Decision on general conditional reimbursement for alendronate-containing medicines

Decision on general conditional reimbursement for alendronate-containing medicines

In cooperation with the Reimbursement Committee, we have decided to grant alendronate-containing medicines general conditional reimbursement from 5 March 2012. Reimbursement is conditional as it is reserved for patients with low-energy hip fractures. For any other patients who are treated with alendronate, the doctor must apply for single reimbursement, and the guiding criteria for single reimbursement remain unchanged for these patients. Alendronate is used for the treatment of osteoporosis (brittle bon...

Danish Medicines Agency

22-2-2012

Changed criteria for single reimbursement for osteoporosis medicines other than alendronate

Changed criteria for single reimbursement for osteoporosis medicines other than alendronate

As of 5 March 2012, it will only be possible to obtain a single reimbursement grant for the other medicines used in osteoporosis treatment for patients that cannot use alendronate. The criteria for single reimbursement are changed because of the large price gaps between the different medicines, where the reimbursement price of alendronate is by far the lowest.

Danish Medicines Agency

2-2-2012

Applications for general reimbursement in 2011

Applications for general reimbursement in 2011

In 2011, we reviewed 21 applications for general reimbursement for 20 different medicinal products. 15 of the applications ended with the granting of general reimbursement or general conditional reimbursement, and the remaining six applications were refused.

Danish Medicines Agency

13-1-2012

Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)

Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)

On 22 December 2009, the Danish Medicines Agency announced that we would begin our reassessment of the reimbursement status of a number of groups of medicines, including antidiabetics (ATC group A10). Within a few months, the Reimbursement Committee will begin to discuss the reimbursement status of antidiabetics.

Danish Medicines Agency

5-1-2012

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.

Danish Medicines Agency

4-11-2011

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

The Danish Medicines Agency has received a number of comments for the Reimbursement Committee's discussion of reimbursement status of strong analgesics (opioids). These comments were presented to the Reimbursement Committee at its meeting on 27 September 2011. The Reimbursement Committee is currently processing a recommendation.

Danish Medicines Agency

7-10-2011

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelat...

Danish Medicines Agency

4-10-2011

The reimbursement for glucosamine is removed on 28 November 2011

The reimbursement for glucosamine is removed on 28 November 2011

The Reimbursement Committee and the Danish Medicines Agency have reassessed the reimbursement status of glucosamine-containing medicines. We have decided to remove the reimbursement for these over-the-counter medicines on 28 November 2011. Glucosamine is used for the alleviation of painful osteoarthritis.

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

The Reimbursement Committee’s recommendation on the future reimbursement status of glucosamine-containing medicines was open for consultation until 8 August 2011. The Danish Medicines Agency received 4 consultation responses.

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

The Reimbursement Committee’s recommendation on the future reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B was open for consultation until 15 August 2011. The Danish Medicines Agency received 9 consultation responses.

Danish Medicines Agency

26-8-2011

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

On 15 August 2011, the Danish Medicines Agency announced that we would begin reassessing the reimbursement status of medicines in ATC group N02A, opioids. The Reimbursement Committee opened its preliminary discussions at its meeting on 23 August 2011 and recommended to include the opioids methadone (N07BC02) and codeine (R05DA04), also used in pain management, in the reassessment of reimbursement status of medicinal products in ATC group N02A.

Danish Medicines Agency

5-7-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).

Danish Medicines Agency

27-5-2011

Consultation on the Reimbursement Committee's recommendation for glucosamine

Consultation on the Reimbursement Committee's recommendation for glucosamine

The Reimbursement Committee has reassessed the reimbursement status of glucosamine-containing medicines. Glucosamine-containing medicines are used for the alleviation of painful osteoarthritis. The Reimbursement Committee recommends removing general conditional reimbursement for these medicines.

Danish Medicines Agency

6-5-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B.

Danish Medicines Agency

3-6-2010

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors) was open for consultation until 7 May 2010.

Danish Medicines Agency

9-4-2010

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders) was open for consultation until 15 March 2010.

Danish Medicines Agency

31-3-2010

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

17-12-2009

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders).

Danish Medicines Agency

2-10-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C05 (Vasoprotectives)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C05 (Vasoprotectives)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group C05 (Vasoprotectives).

Danish Medicines Agency

30-6-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C04 (Peripheral vasodilators)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C04 (Peripheral vasodilators)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group C04 (Peripheral vasodilators)

Danish Medicines Agency

30-6-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives)

At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives).

Danish Medicines Agency

4-6-2009

Reimbursement status of medicinal products in ATC groups A06 and A02AA04, laxatives: Consultation responses to the Reimbursement Committee's recommendation

Reimbursement status of medicinal products in ATC groups A06 and A02AA04, laxatives: Consultation responses to the Reimbursement Committee's recommendation

The Reimbursement Committee's recommendation on the future reimbursement status of laxatives (ATC groups A06 and A02AA04) has been open for consultation until 27 May 2009.

Danish Medicines Agency

4-6-2009

Reimbursement status of medicinal products in ATC group A08, antiobesity preparations, excl. diet products: Consultation responses to the Reimbursement Committee's recommendation

Reimbursement status of medicinal products in ATC group A08, antiobesity preparations, excl. diet products: Consultation responses to the Reimbursement Committee's recommendation

The Reimbursement Committee's recommendation on the future reimbursement status of antiobesity preparations, excl. diet products (ATC group A08) has been open for consultation until 25 May 2009.

Danish Medicines Agency

30-4-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A08 (antiobesity preparations, excl. diet products).

Danish Medicines Agency

8-9-2008

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

23-5-2007

Reassessment of the reimbursement status of blood pressure products resumed in the Reimbursement Committee

Reassessment of the reimbursement status of blood pressure products resumed in the Reimbursement Committee

At its meeting on 12 December 2006, the Reimbursement Committee resumed the reassessment of the reimbursement status of blood pressure products.

Danish Medicines Agency

15-2-2007

Reassessment of reimbursement status of medicinal products in ATC-groups A01, A04, C04, C05 and C10

Reassessment of reimbursement status of medicinal products in ATC-groups A01, A04, C04, C05 and C10

In connection with the reassessment of the reimbursement status of medicinal products, the Reimbursement Committee discussed the reimbursement status of certain ATC groups at its meeting on 16 January 2007.

Danish Medicines Agency

18-12-2006

Reassessment of reimbursement status

Reassessment of reimbursement status

This summer, the Danish Medicines Agency will begin the periodic reassessment of reimbursement status of medicinal products. Over a 5-year period, the reimbursement status of all medicinal products will be reassessed to ensure that the medicinal products having been granted general reimbursement still meet the required criteria and that medicinal products which have not been granted general reimbursement do not meet the criteria.

Danish Medicines Agency

18-12-2006

Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products

Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products

At several meetings, the Reimbursement Committee has discussed the reimbursement status of lipid-lowering medicinal products. In its recommendation of 7 September 2006 for the Danish Medicines Agency, the Committee suggests a change of reimbursement status for these medicinal products.

Danish Medicines Agency

Es gibt keine Neuigkeiten betreffend dieses Produktes.